ClinicalTrials.gg
RecruitingNCT07152834AATD-SAOUpdated Sep 10, 2025

Screening for Alpha-1 Antitrypsin Deficiency in Patients With Airway Obstruction

An observational study in Alpha 1-antitrypsin Deficiency (AATD), sponsored by Muğla Sıtkı Koçman University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Muğla Sıtkı Koçman University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
734
Ages
18 Years and older
Sex
All
01

Study summary

Brief Summary:

This study aims to find out if a genetic condition called Alpha-1 Antitrypsin Deficiency (AATD) is more common in people who have shortness of breath and signs of airway obstruction on their breathing tests.

Alpha-1 antitrypsin (AAT) is a protein that protects the lungs from damage. AATD is an inherited condition where the body does not make enough of this protein, which can lead to lung diseases like emphysema, especially in smokers.

Investigators hypothesize that low AAT levels or related genetic mutations may be a contributing factor to airway obstruction in patients complaining of shortness of breath.

To test this, investigators will recruit patients from our outpatient clinic who are being evaluated for shortness of breath and are having a standard breathing test (spirometry). Investigators will measure their AAT levels and test for the most common genetic mutations that cause AATD using a small blood sample. Investigators will then compare the AAT levels and genetic results between different groups of patients, such as smokers and non-smokers with and without airway obstruction. Investigators will also see if the severity of a patient's shortness of breath is related to their AAT levels.

The goal is to improve the detection of AATD in this patient population, which could lead to better diagnoses and specific treatments for those who have this condition.

Read the detailed description
  1. Study Objectives and Rationale Alpha-1 Antitrypsin Deficiency (AATD) is a significantly underdiagnosed hereditary disorder that predisposes individuals to early-onset emphysema and chronic obstructive pulmonary disease (COPD), particularly in smokers. The primary objective of this single-center, cross-sectional, analytical study is to determine the prevalence of both quantitative (serum level) and qualitative (genetic mutation) AATD in a targeted, high-risk population: patients presenting to a pulmonary outpatient clinic with shortness of breath (dyspnea) and found to have functional airway obstruction on spirometry.

    The study operates on the hypothesis that a subset of patients with airway obstruction, especially those with an early onset or a disproportionate severity of disease relative to their smoking history, may have undiagnosed AATD. By systematically screening this population using both serum level analysis and genetic testing, we aim to identify a previously undetected patient cohort, enabling earlier intervention, family screening, and specific management strategies.

  2. Study Design and Methodology This is a prospective, case-control, analytical study conducted at the Chest Diseases Outpatient Clinic of Muğla Training and Research Hospital.

Participant Flow:

  1. Screening \& Identification: Consecutive patients presenting with a chief complaint of dyspnea who are scheduled for routine diagnostic spirometry as part of standard clinical care will be assessed for eligibility.
  2. Informed Consent: Eligible patients will be provided with a detailed informed consent form explaining the study's purpose, procedures, risks, and benefits.
  3. Group Allocation: Following spirometry, participants will be allocated into two groups based on their test results:

    Case Group (PRISm): Patients with a post-bronchodilator FEV1/FVC ratio ≥ 0.70, FEV1 \< 80 Control Group (No Airway Obstruction): Patients with a post-bronchodilator FEV1/FVC ratio ≥ 0.70, FEV1 ≥ 80

  4. Data and Sample Collection: All participants will undergo:

    Clinical Assessment: Recording of mMRC dyspnea scale and detailed smoking history.

    Blood Sampling:

    For AAT Level: Residual serum from routine blood samples drawn for standard clinical care will be aliquoted into polypropylene cryotubes.

    For Genetic Testing: A separate capillary blood sample will be obtained via finger prick using a sterile lancet and collected on a designated filter paper.

  5. Blinding: Laboratory personnel performing the AAT level assays and genetic analyses will be blinded to the participant's group assignment (case or control) and clinical data.

Laboratory Methods:

AAT Serum Level Measurement: Serum AAT concentrations will be quantified using a validated immunoturbidimetric assay on an automated clinical chemistry analyzer.

Genetic Analysis: DNA will be extracted from the capillary blood samples. Genotyping for the most common pathogenic *SERPINA1* alleles (e.g., PI*S, PI*Z) will be performed using a real-time polymerase chain reaction (RT-PCR) based method.

3. Data Management and Quality Assurance

Data Collection and Source Documents: Clinical data (spirometry results, mMRC, smoking history) will be recorded directly into a structured electronic Case Report Form (eCRF). Spirometry equipment will be calibrated daily according to American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines. Source documents include hospital medical records and laboratory information system reports.

4. Statistical Analysis Plan A review of the national and international literature revealed no prior studies specifically investigating the clinical characteristics of airway obstruction in relation to alpha-1 antitrypsin genetic mutations and/or levels, underscoring the novelty of this research.

The sample size calculation was performed using the G*Power 3.1.2 software. Based on FEV1 measurements (mean ± SD = 56 ± 13) reported in a reference study of dyspnoeic patients, the effect size was calculated as 0.1538462. This calculation determined that a minimum of 334 participants per group would be required to achieve 80% statistical power with a 5% margin of error (alpha = 0.05). Anticipating a potential 10% dropout rate, the target sample size was increased to at least 367 patients for the case group and 367 matched controls for the control group.

All statistical analyses will be conducted using IBM SPSS Statistics for Windows, Version 27.0 (Armonk, NY: IBM Corp.). The normality of distribution for quantitative variables will be assessed using the Kolmogorov-Smirnov test. For comparisons between independent groups:

Normally distributed variables will be analyzed using the Independent Samples t-test (for two groups) or One-Way ANOVA (for more than two groups).

Non-normally distributed variables will be analyzed using the Mann-Whitney U test (for two groups) or the Kruskal-Wallis H test (for more than two groups).

The relationship between qualitative variables will be investigated using Chi-square analysis. Correlations between quantitative variables will be examined using Pearson's correlation coefficient for normally distributed data or Spearman's rank correlation coefficient for non-normal data.

To identify factors independently associated with the presence of breathlessness (dyspnea), multivariate analyses will be employed. This will include data-structure-appropriate binary logistic regression models. Additionally, advanced analytical techniques such as decision tree methods (e.g., C\&RT, C4.5) may be applied for predictive modeling and pattern recognition.

Descriptive statistics will be reported as follows:

Normally distributed quantitative variables: Mean ± Standard Deviation. Non-normally distributed quantitative variables: Median (25th - 75th percentile) or Median (Minimum - Maximum).

Categorical variables: Frequency (n, %). A p-value of less than 0.05 will be considered statistically significant for all analyses.

**5. Ethical and Operational Considerations** The study protocol has been approved by the Muğla Sıtkı Koçman University Local Ethics Committee. All biological samples will be stored anonymized and coded in a dedicated -80°C freezer with restricted access. Samples will be destroyed according to ethical guidelines upon study completion.

02

Conditions studied

  • Alpha 1-antitrypsin Deficiency (AATD)

Keywords

  • Alpha 1-Antitrypsin Deficiency
  • Airway Obstruction
  • PRISm
03

In context

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

This study's planned enrollment of 734 is above the median of 160 across 46 observational studies indexed under alpha 1-Antitrypsin Deficiency.

Browse alpha 1-Antitrypsin Deficiency studies →

Lead sponsor

Muğla Sıtkı Koçman University is the lead sponsor of 115 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of consecutive adult patients presenting with a primary complaint of dyspnoea (shortness of breath) at the Chest Diseases Outpatient Clinic of Muğla Training and Research Hospital in Turkey. These patients will be referred for routine diagnostic pulmonary function testing (spirometry) as part of their standard clinical care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Achieve a post-bronchodilator /FVC ratio of 70 or above in the respiratory function test.
  • Be able to speak and understand Turkish.
  • Have the mental and cognitive capacity to understand the questions asked.

Exclusion criteria

Exclusion Criteria:

  • Renal dysfunction; acute inflammation; rheumatological, haematological, or liver diseases; ; asthma; bronchiectasis; and a history of .
  • Pregnant women and users of oral .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
734 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • PRISm

    Patients with a post-bronchodilator FEV1/FVC ratio ≥ 0.70, FEV1 \< 80

    Diagnostic Test: Blood Sampling

  • Normal PFT

    Patients with a post-bronchodilator FEV1/FVC ratio ≥ 0.70, FEV1 ≥ 80

    Diagnostic Test: Blood Sampling

Interventions

  • Diagnostic testBlood Sampling

    For AAT Level: Residual serum from routine blood samples drawn for standard clinical care will be aliquoted into polypropylene cryotubes. For Genetic Testing: A separate capillary blood sample will be obtained via finger prick using a sterile lancet and collected on a designated filter paper.

06

What researchers measure

Primary outcomes

  1. Prevalence of Alpha-1 Antitrypsin Deficiency (AATD)

    The prevalence of Alpha-1 Antitrypsin Deficiency (AATD) is defined as the proportion of participants in each group who test positive for the condition. AATD is diagnosed by either: Genetic Analysis: Identification of a pathogenic SERPINA1 mutation (e.g., PIZ or PIS allele) via PCR-based genotyping of a capillary blood sample. Serum Level Analysis: A serum AAT concentration below 0.9 g/L, measured using an immunoturbidimetric assay on a residual serum sample from routine blood work. The difference in prevalence rates between the case and control groups will be statistically compared.

    Time frame: Day 1

Secondary outcomes

  1. Correlation between AATD and smoking status.

    The correlation between AATD and smoking habits will be analyzed by comparing the % of patients with AATD (as defined above) across different smoking status categories (never-smoker, former smoker, current smoker) within the study groups. Smoking history is quantified by patient-reported pack-years.

    Time frame: Day 1

Other outcomes

  1. Correlation between dyspnea severity and AAT level.

    The correlation between dyspnea severity and AAT level will be assessed by calculating the correlation coefficient between the quantitative serum AAT level (g/L) and the mMRC (Modified Medical Research Council) dyspnea scale score. The mMRC is a 5-point scale (0-4) where 0 means breathlessness only with strenuous exercise and 4 means too breathless to leave the house or breathless when dressing. A higher score indicates worse dyspnea.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
  • Muğla Training and Research Hospital
    Muğla, Menteşe 48000, Turkey (Türkiye)
    Recruiting
    • ozlem sengoren dikis, associate prof. · Contactozlemsengoren@mu.edu.tr · +905373849700
    • Ozlen Sengoren Dikis, Associate Prof · Principal investigator
    • Sabri Serhan Olcay, Assistant Prof · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data (IPD) that underlie the results reported in publications from this study will not be made publicly available. This decision is based on several factors: the data contain sensitive genetic and health information, the informed consent process obtained from participants did not include provisions for public data sharing, and the current ethical approval and local data protection regulations at Muğla Training and Research Hospital restrict the public sharing of such identifiable personal health data. Requests for anonymized data may be considered on a case-by-case basis for legitimate research purposes, subject to a formal data sharing agreement and approval from the local ethics committee.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Dec 2025, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2025
First posted
Sep 3, 2025
StartActual
Aug 6, 2025
Primary completionEst.
Dec 30, 2025
CompletionEst.
Jan 5, 2026
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07152834
Collaborators
PROGENIKA BIOPHARMA, A GRIFOLS Company
Responsible party
Ozlem Sengoren Dikis (Associate Professor, Muğla Sıtkı Koçman University) — Principal investigator
First posted
Sep 3, 2025
Start date
Aug 6, 2025
Primary completion
Dec 30, 2025 (estimated)
Completion
Jan 5, 2026 (estimated)
Last update
Sep 10, 2025

Study contacts

Ozlem Sengoren Dikis, Associate Professor
Contact
ozlemsengoren@mu.edu.tr
+905073849700
sabri serhan olcay, Assistant Prof.
Contact
serhanolcay@mu.edu.tr
+905057578329

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion